Ambrosch F, Frisch-Niggemeyer W, Kremsner P, Kunz C, André F, Safary A, Wiedermann G
Institute for Specific Prophylaxis and Tropical Medicine, University of Vienna, Austria.
Postgrad Med J. 1987;63 Suppl 2:129-35.
Protection against hepatitis B virus infection can be achieved by the induction of neutralizing antibodies against the hepatitis B surface antigen (HBsAg). An antibody concentration of 10 IU/l, as measured by radioimmunoassay, is considered to be protective. HBsAg can be produced either from the plasma of chronic carriers or by DNA recombinant technology in yeast cells. Plasma- and yeast-derived vaccines have been compared in several studies and their immunological properties were found to be similar, including the persistence of antibodies induced by either type of vaccine. Finally, yeast-derived hepatitis B vaccine can boost anti-HBs responses initially elicited by either plasma- or yeast-derived vaccine equally and effectively. In order to maintain protective immunity after hepatitis B vaccination, antibody determination and, if necessary, booster vaccination should be performed, particularly in high-risk persons.
通过诱导针对乙型肝炎表面抗原（HBsAg）的中和抗体，可以实现对乙型肝炎病毒感染的预防。通过放射免疫测定法测得的抗体浓度为10 IU/l时被认为具有保护作用。HBsAg可以从慢性携带者的血浆中产生，也可以通过酵母细胞中的DNA重组技术产生。在多项研究中对血浆源性疫苗和酵母源性疫苗进行了比较，发现它们的免疫特性相似，包括这两种疫苗诱导产生的抗体的持久性。最后，酵母源性乙型肝炎疫苗可以同等有效地增强最初由血浆源性或酵母源性疫苗引发的抗-HBs反应。为了在乙型肝炎疫苗接种后维持保护性免疫，应进行抗体检测，必要时进行加强免疫，尤其是在高危人群中。
